Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance
Reference number: TA276
Published: 27 March 2013

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Updated Patient Access Scheme (PAS) submission from Forest Laboratories UK

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Updated Patient Access Scheme (PAS) submission from Forest Laboratories UK

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Updated Patient Access Scheme (PAS) submission from Forest Laboratories UK
25 January 2013
(812.41 Kb 56 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 23 January 2013